Management of nausea and vomiting in patients treated with zolbetuximab [Video]

Samuel Klempner, MD, Massachusetts General Hospital, Boston, MA, comments on the development of consensus guidelines for managing nausea and vomiting in patients treated with zolbetuximab, a claudin 18.2 targeting antibody, plus chemotherapy. Initial findings from Phase II and III zolbetuximab trials highlight frequent nausea and vomiting as a side effect, often leading to treatment discontinuation despite antiemetic use. The study aims to establish evidence-based guidance for effective nausea and vomiting management during zolbetuximab therapy. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.